Thus, it has become increasingly apparent that the combined targeting of ErbB receptors and downstream effectors such as PI3K or AKT has the potential to result in greater anti-tumor effects than single agent therapies do [29,30,31]. The gene discussed is AKT1; the disease is neoplasm.